21 August 2026 | 2:17PM HKT Equity Research Pharmaron (3759.HK) 2Q26 earnings review: Strong CDMO order momentum supports FY26 guidance raise to 15-20% | 3759.HK | 12m Price Target: HK$33.20 | Price: HK$33.86 | Downside: 1.9% | | --- | --- | --- | --- | | 300759.SZ | 12m Price Target: Rmb41.90 | Price: Rmb50.90 | Downside: 17.7% | In line with the preliminary results, 2Q26 revenue increased 20.2% y/y, driven primarily by continued strength in the CDMO business (+42% y/y). Adjusted non-IFRS net profit rose 2 ...